Corient Private Wealth’s Elanco Animal Health ELAN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$8.42M Buy
342,271
+189,540
+124% +$4.38M 0.01% 696
2026
Q1
$3.6M Buy
152,731
+51,836
+51% +$1.27M 0.01% 971
2025
Q4
$2.28M Buy
100,895
+26,507
+36% +$577K ﹤0.01% 1080
2025
Q3
$1.5M Buy
74,388
+9,240
+14% +$155K ﹤0.01% 1211
2025
Q2
$930K Buy
65,148
+27,772
+74% +$325K ﹤0.01% 1392
2025
Q1
$392K Sell
37,376
-4,945
-12% -$55.9K ﹤0.01% 1721
2024
Q4
$513K Sell
42,321
-1,057
-2% -$13.8K ﹤0.01% 1602
2024
Q3
$637K Buy
43,378
+3,319
+8% +$46.2K ﹤0.01% 1611
2024
Q2
$578K Sell
40,059
-1,083
-3% -$17.3K ﹤0.01% 1569
2024
Q1
$670K Buy
41,142
+171
+0.4% +$2.67K ﹤0.01% 1485
2023
Q4
$610K Sell
40,971
-1,249
-3% -$14.1K ﹤0.01% 1508
2023
Q3
$475K Buy
42,220
+7,845
+23% +$91.1K ﹤0.01% 1523
2023
Q2
$346K Buy
34,375
+23,248
+209% +$216K ﹤0.01% 1630
2023
Q1
$105K Buy
+11,127
New +$131K ﹤0.01% 1877

Other funds holding ELAN

Corient Private Wealth's ELAN Position: Q2 2026 in Review

Corient Private Wealth increased its Elanco Animal Health (ELAN) stake by 124% in Q2 2026, buying an estimated $4.38M and bringing the position to 342,271 shares worth $8.42M. The position accounts for 0.01% of the portfolio, ranked #696.

Corient Private Wealth first reported a position in ELAN in Q1 2023 and has held it in 14 quarters since. 522 funds tracked by Wall St. Rank hold ELAN as of Q2 2026.

  • Corient Private Wealth held 342,271 shares of Elanco Animal Health worth $8.42M as of Q2 2026.
  • Corient Private Wealth bought 189,540 Elanco Animal Health shares in Q2 2026, an estimated $4.38M.
  • Elanco Animal Health made up 0.01% of Corient Private Wealth's portfolio in Q2 2026, its #696 holding.
  • Corient Private Wealth first reported a position in Elanco Animal Health in Q1 2023 and has held it in 14 quarters since.
  • 522 funds tracked by Wall St. Rank held Elanco Animal Health as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.